

Clinical Policy: Talimogene laherepvec (Imlygic)

Reference Number: CP.PHAR.542

Effective Date: 09.01.21

Last Review Date: 08.26

Line of Business: Commercial, HIM/ICHRA, Medicaid

[Coding Implications](#)[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Talimogene laherepvec (Imlygic[®]) is genetically modified oncolytic viral therapy.

FDA Approved Indication(s)

Imlygic is indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.

Limitation(s) of use: Imlygic has not been shown to improve overall survival or have an effect on visceral metastases.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Imlygic is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria**A. Melanoma** (must meet all):

1. Diagnosis of unresectable, limited resectable, or metastatic melanoma;
2. Prescribed by or in consultation with an oncologist;
3. Age $\geq$ 18 years;
4. Prescribed in one of the following ways (a or b):
 - a. A single agent;
 - b. In combination with Yervoy[®]* as subsequent therapy for metastatic or unresectable melanoma (*off-label*);
**Prior authorization may be required for Yervoy*
5. Documentation of both the following (a and b):
 - a. Lesions are cutaneous, subcutaneous, or nodal;
 - b. Quantity and sizes of lesions;
6. Request meets one of the following (a or b):*
 - a. Both of the following (i and ii):
 - i. For initial dose: Dose does not exceed 4 mL of 10^6 plaque-forming units (PFU)/mL (*see Appendix D*);
 - ii. For all subsequent doses (starting 3 weeks after initial dose) and reinitiation: Dose does not exceed 4 mL of 10^8 PFU/mL every 2 weeks (*see Appendix D*);

- b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 12 months

B. Merkel Cell Carcinoma (off label) (must meet all):

1. Diagnosis of Merkel cell carcinoma;
2. Prescribed by or in consultation with an oncologist;
3. Age $\geq$ 18 years;
4. Prescribed as a single agent;
5. One of the following (a or b):
 - a. Disease has progressed following treatment with anti-PD-1/PD-L1 therapy (e.g., Keytruda[®], Opdivo[®]);
 - b. Use of anti-PD-1/PD-L1 therapy (e.g., Keytruda, Opdivo) is contraindicated;
6. One of the following (a or b):
 - a. Curative surgery or radiation therapy is not feasible;
 - b. Disease is metastatic;
7. Documentation of both the following (a and b):
 - a. Lesions are cutaneous, subcutaneous, or nodal;
 - b. Quantity and sizes of lesions;
8. Request meets one of the following (a or b):*
 - a. Both of the following (i and ii):
 - i. For initial dose: Dose does not exceed 4 mL of 10^6 plaque-forming units (PFU)/mL (*see Appendix D*);
 - ii. For all subsequent doses (starting 3 weeks after initial dose) and reinitiation: Dose does not exceed 4 mL of 10^8 PFU/mL every 2 weeks (*see Appendix D*);
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 12 months

C. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line

of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. All Indications in Section I (must meet all):

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Imlygic for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. Documentation of both the following (a and b):
 - a. New or remaining lesions are cutaneous, subcutaneous, or nodal;
 - b. Quantity and sizes of new or remaining lesions;
4. If request is for a dose increase, request meets one of the following (a or b):*
 - a. New dose does not exceed 4 mL of 10⁸ PFU/mL every 2 weeks (*see Appendix D*);
 - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- ### **A.**
- Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

NCCN: National Comprehensive Cancer Network
PFU: plaque-forming units

Appendix B: Therapeutic Alternatives
Not applicable

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): immunocompromised patients, pregnancy
- Boxed warning(s): none

Appendix D: Determination of Imlygic Injection Volume Based on Lesion Size

Lesion Size (longest dimension)	Injection Volume
> 5 cm	up to 4 mL
> 2.5 cm to 5 cm	up to 2 mL
> 1.5 cm to 2.5 cm	up to 1 mL
> 0.5 cm to 1.5 cm	up to 0.5 mL
≤ 0.5 cm	up to 0.1 mL

When lesions are clustered together, they should be injected together as a single lesion according to this table.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Melanoma	Recommended starting dose for injection into cutaneous, subcutaneous, and/or nodal lesions is up to 4 mL at a concentration of 10^6 (1 million) PFU per mL, followed by up to 4 mL of 10^8 (100 million) PFU/mL administered 3 weeks later; thereafter, subsequent doses (including reinitiation) of up to 4 mL of 10^8 PFU/mL are administered every 2 weeks	4 mL at a concentration of 10^8 PFU/mL per treatment (all lesions combined)

VI. Product Availability

Single-use vials: 10^6 (1 million) PFU/mL, 10^8 (100 million) PFU/mL

VII. References

1. Imlygic Prescribing Information. Thousand Oaks, CA: Amgen; November 2024. Available at: <https://www.imlygic.com/>. Accessed April 24, 2026.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: https://www.nccn.org/professionals/drug_compendium/content/. Accessed April 24, 2026.
3. National Comprehensive Cancer Network. Melanoma: Cutaneous Version 02.2026. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed April 24, 2026.
4. National Comprehensive Cancer Network. Merkel Cell Carcinoma Version 02.2026. Available at: https://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf. Accessed April 24, 2026.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9325	Injection, talimogene laherparepvec, per 1 million plaque forming units

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Template changes applied to other diagnoses/indications.	10.05.22	
3Q 2023 annual review: updated dosing in initial approval criteria so that member meets both initial and subsequent dosing; added reinitiation dose in initial approval criteria to align with dosing section in prescriber information; references reviewed and updated.	05.09.23	08.23
3Q 2024 annual review: added criteria for metastatic melanoma and off label criteria for combination use with Yervoy per NCCN compendium; in continued therapy, clarified criteria to require documentation of the type, quantity, and size of new or remaining lesions; references reviewed and updated.	05.23.24	08.24
3Q 2025 annual review: added off-label criteria for Merkel cell carcinoma per NCCN; references reviewed and updated.	05.13.25	08.25
3Q 2026 annual review: added ICHRA line of business; for all indications, extended initial approval duration from 6 months to 12 months for this maintenance medication for a chronic condition; for MCC, added requirement for disease progression following treatment with anti-PD-1/PD-L1 therapy unless contraindication per NCCN compendium; references reviewed and updated.	04.24.26	08.26

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering

benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2021 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.